DOCSLIB.ORG

Wellcome Trust Annual Review 2009

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Wellcome Trust Annual Review 2009 WELLCOME TRUST ANNUAL REVIEW 1 October 2008–30 September 2009 September 2008–30 October 1 REVIEW ANNUAL TRUST WELLCOME ANNUAL REVIEW 2009 The Wellcome Trust We are a global charity dedicated to achieving extraordinary improvements in human and animal health. We support the brightest minds in biomedical research and the medical humanities. Our breadth of support includes public engagement, education and the application of research to improve health. We are independent of both political and commercial interests. www.wellcome.ac.uk www.wellcome.ac.uk The Wellcome Trust Acknowledgements MAKING A DIFFERENCE EXECUTIVE BOARD BOARD OF GOVERNORS We are grateful to everyone who agreed The Wellcome Trust Annual Review is All images are courtesy of Wellcome Images to be reviewed in this issue, everyone distributed via a mailing list held by the (images.wellcome.ac.uk) except as follows: The Wellcome Trust’s mission is to Mark Walport William Castell p. 3: 1 (K Hodivala-Dilke and M Stone); pp. 6–7: 1 who supplied images or gave us Wellcome Trust. If you would like to be foster and promote research with the Director of the Wellcome Trust Chairman (Dr Linda Stannard, UCT/SPL), 2 (Arran Lewis), permission for their images to be used, added to the list, or if you have a 3 (Anthea Sieveking); p. 8 (David Gregory and Debbie aim of improving human and animal Ted Bianco Adrian Bird and the many members of Wellcome colleague who would like to receive the Marshall); p. 10: 2 (Annie Cavanagh); p. 12 (Robert health. During 2005–2010, Pears/iStockphoto); p. 13 (BSIP VEM/SPL); p. 15 Director of Technology Transfer Deputy Chairman Trust staff who helped to produce this Wellcome Trust Annual Review, please our aims are: (Anna Tanczos); p. 17 (SPL); p. 18: 2 (Caroline Penn); volume. contact: p. 19: 1 (Dr Linda Stannard, UCT/SPL), 2 (Pasquale John Cooper Kay Davies Advancing knowledge: To support Sorrentino/SPL); p. 20: 1 (Ida Ma, Novartis Institute for UKCMRI Chief Operating Officer Editor Publishing Department Tropical Diseases), 2 (Chris de Bode/Panos); p. 21: 1 research to increase understanding Peter Davies and Interim Chief Executive Officer Ian Jones, Isinglass Consultancy Wellcome Trust (Western Ophthalmic Hospital/SPL), 2 (Warwick Design of health and disease, and its societal Consultants); p. 22: 1 (Annie Cavanagh); p. 26: 1 Christopher Fairburn FREEPOST context Simon Jeffreys Project Manager (Natural History Museum); p. 27: 1, 2 (Blink Films); RLYJ-UJHU-EKHJ p. 29 (Andrew Whittuck); p. 32: 1 (Daan van Aalten); Chief Operating Officer Richard Hynes Lucy Moore Using knowledge: To support the Slough SL3 0EN p. 35 (Volker Brinkmann); p. 36 (Membrane Protein Laboratory); p. 41: 1 (Anna Tanczos); p. 45 development and use of knowledge David Lynn Roderick Kent Writers T +44 (0)20 7611 8651 (Annie Cavanagh, Wellcome Images); p. 46: top to create health benefit Head of Strategic Planning and Policy Penny Bailey (Anton Enwright), middle (Annie Cavanagh), bottom Eliza Manningham-Buller F +44 (0)20 7611 8242 Ian Jones (Benedict Campbell); p. 47: top (Yorgos Nikas), Engaging society: To engage with Clare Matterson E [email protected] middle (iStockphoto); p. 50 (Simon Clark). Peter Rigby Mun-Keat Looi society to foster an informed climate Director of Medicine, www.wellcome.ac.uk/publications within which biomedical research Society and History Peter Smith Assistant editor can flourish Tom Freeman ISBN 978 1 84129 084 3 Alan Schafer Edward Walker-Arnott Developing people: To foster a research Director of Science Funding Design The Wellcome Trust is a charity community and individual researchers Anja Fouad registered in England, no. 210183. Its John Stewart As at January 2010 who can contribute to the advancement sole trustee is The Wellcome Trust Head of Legal and Company Secretary Photography and use of knowledge Limited, a company registered in David Sayer Danny Truell England, no. 2711000, whose registered Facilitating research: To promote the Chief Investment Officer Publisher office is at 215 Euston Road, London best conditions for research and the Hugh Blackbourn NW1 2BE, UK. use of knowledge As at January 2010 Comments on the Wellcome Trust First published by the Wellcome Trust, Developing our organisation: To use Annual Review are welcomed and 2010. our resources efficiently and effectively. should be sent to: © The trustee of the Wellcome Trust, Hugh Blackbourn London. www.wellcome.ac.uk/strategicplan. Publishing Department This is an open access publication and, Wellcome Trust with the exception of images and Gibbs Building illustrations, the content may, unless 215 Euston Road otherwise stated, be reproduced free of London NW1 2BE, UK charge in any format or medium, subject F +44 (0)20 7611 8270 to the following conditions: content must E [email protected] be reproduced accurately; content must not be used in a misleading context; the Wellcome Trust must be attributed as the original author and the title of the document specified in the attribution. Cert no. SGS-COC-2524 Wellcome Trust Gibbs Building 215 Euston Road London NW1 2BE, UK Printed by the colourhouse using their pureprint ® environmental print technology. The printing inks are made from vegetable-based oils and T +44 (0)20 7611 8888 95 per cent of cleaning solvents are recycled for further use. The COVER IMAGE colourhouse is a carbon-neutral company, accredited with environmental Colour-enhanced image of a blood clot, showing F +44 (0)20 7611 8545 management system ISO 14001. This document was printed on material made from 25 per cent post-consumer waste, 25 per cent pre-consumer many red blood cells and a single white blood E [email protected] waste and 50 per cent virgin fibre from Forest Stewardship Council Mixed cell in a mesh of fibrin. The red blood cells are Sources and was manufactured at a mill with ISO 14001. crenated – spiky – because they are dehydrated. www.wellcome.ac.uk Anne Weston DO-4692/8.5K/01-2010/AF Contents | 1 p. 5 THE YEAR IN REVIEW Director’s statement 2 Advancing knowledge 4 Using knowledge 16 p. 7 p. 22 Engaging society 24 Developing people 30 Facilitating research 36 Developing our organisation 40 Corporate activities 2008/09 41 Financial summary 2008/09 42 p. 20 p. 26 Funding developments 2008/09 44 Streams funding 2008/09 46 Technology Transfer 48 Wellcome Trust Genome Campus 49 Public Engagement 50 p. 29 p. 33 Wellcome Collection 51 Advisory committees 52 p. 34 p. 38 2 | AdvancingDirector’s statement knowledge Five years of progress As we reach the end of our five-year health and disease – including diabetes, for the disease and adopted globally. In Strategic Plan, we can celebrate cancer and malaria – exceeding its target Vietnam, meanwhile, researchers have much success and look forward to of 375 structures. In 2007, we committed completed an important phase II clinical exciting new directions. £16 million to enable the Consortium to trial of a new typhoid fever vaccine, solve an additional 600 structures. This developed with funding from our The end of 2009 sees not only the end of will further our understanding of these Technology Transfer division. The vaccine a year’s activities but also the fruition of a proteins and supply new targets for proved both safe and effective in eliciting five-year Strategic Plan that began in therapeutic intervention. good immune responses in children, 2005. In that Plan, we set out that we encouraging results that can pave the wanted our funding to lead to increased Advances in genomics have also made way for larger phase III clinical trials. understanding of health and disease, possible projects such as the Cancer and its societal context, and to use that Genome Project, an ambitious initiative In Kenya, researchers at the KEMRI– knowledge to develop improved health to map the individual mutations involved Wellcome Trust Research Programme benefits. I feel that we have met those in many different types of cancer. An found that invasive bacterial infections, aims. The last five years have seen our early success was the discovery of BRAF most of which could be prevented with funding contribute to some vital as an important gene involved in malignant existing vaccines, were the leading breakthroughs in biology and medicine melanoma and a high proportion of other cause of death among children at a rural and the pursuit of much inspirational cancers. The Project has also made Kenyan hospital. The findings highlighted science. significant progress in distinguishing the the neglected threat of bacterial disease ‘driver’ mutations that cause cancer from to public health and the need to One of our biggest areas of success the ‘passenger’ mutations that are a overcome the political and financial continues to be in genetics and genomics. result of it. barriers to widespread use of vaccines. As DNA-sequencing technology continues Researchers at the Programme have to improve at a remarkable rate, we have The Wellcome Trust Sanger Institute plays also demonstrated that vaccinating seen studies take advantage of the Human a key role in many of these projects and against Haemophilus influenzae serotype Genome Project since the completion of continues to be a leading light in the b (Hib), which can lead to meningitis and the first whole-genome draft in 2000. genomics field. In addition to its work in pneumonia and causes 400 000 deaths Chief among these is the advent of human genetics, it has completed a per year globally, reduces the number of genome-wide association studies, in number of important genome sequences, cases of Hib disease by 88 per cent. The particular the work of the Wellcome Trust notably the parasites Trypanosoma brucei Kenyan Ministry of Health subsequently Case Control Consortium. By examining and Leishmania, which cause two of the committed to funding an ongoing the whole genomes of thousands of major diseases in low-income countries, nationwide immunisation programme.
Load more

Recommended publications
  • Wellcome Trust Annual Report and Financial Statements 2017 Contents
    Annual Report and Financial Statements 2017 2 Wellcome Trust Annual Report and Financial Statements 2017 Contents Report from the Chair and the Director 5 Trustee’s Report 8 What we do 8 Review of Charitable Activities 9 Review of Investment Activities 18 Financial Review 29 Structure and Governance 34 Risk Management 37 Remuneration Report 40 Audit Committee Report 43 Independent Auditor’s Report 45 Financial Statements 58 Consolidated Statement of Financial Activities 58 Consolidated Balance Sheet 59 Statement of Financial Activities of the Trust 60 Balance Sheet of the Trust 61 Consolidated Cash Flow Statement 62 Notes to the Financial Statements 63 Reference and Administrative Details 117 3 Wellcome Trust Annual Report and Financial Statements 2017 “ At Wellcome, we believe in the power of ideas to improve health” Jeremy Farrar Director 4 Wellcome Trust Annual Report and Financial Statements 2017 Report from the Chair and the Director “Our core approach is funding people to explore great ideas, at every step of the way from discovery to impact” At Wellcome, we believe in the power of ideas to improve cause of maternal mortality in the world. It also includes health. Funded from our independent investment portfolio, supporting research in the humanities and social sciences, we support thousands of scientists and researchers in more such as a project which this year published ethical guidelines than 70 countries, as well as innovators, educators and artists. for involving pregnant women in Zika vaccine research. Together, we take on big problems, fuel imaginations and spark And resources like the Human Induced Pluripotent Stem Cell debate, working always to achieve better health for everyone.
    [Show full text]
  • ANNUAL REVIEW 1 October 2005–30 September
    WELLCOME TRUST ANNUAL REVIEW 1 October 2005–30 September 2006 ANNUAL REVIEW 2006 The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. It funds innovative biomedical research, in the UK and internationally, spending around £500 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research and its impact on health and wellbeing. www.wellcome.ac.uk THE WELLCOME TRUST The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. 123 CONTENTS BOARD OF GOVERNORS 2 Director’s statement William Castell 4 Advancing knowledge Chairman 16 Using knowledge Martin Bobrow Deputy Chairman 24 Engaging society Adrian Bird 30 Developing people Leszek Borysiewicz 36 Facilitating research Patricia Hodgson 40 Developing our organisation Richard Hynes 41 Wellcome Trust 2005/06 Ronald Plasterk 42 Financial summary 2005/06 Alastair Ross Goobey 44 Funding developments 2005/06 Peter Smith 46 Streams funding 2005/06 Jean Thomas 48 Technology Transfer Edward Walker-Arnott 49 Wellcome Trust Genome Campus As at January 2007 50 Public Engagement 51 Library and information resources 52 Advisory committees Images 1 Surface of the gut. 3 Zebrafish. 5 Cells in a developing This Annual Review covers the 2 Young children in 4 A scene from Y fruit fly. Wellcome Trust’s financial year, from Kenya. Touring’s Every Breath. 6 Data management at the Sanger Institute. 1 October 2005 to 30 September 2006. CONTENTS 1 45 6 EXECUTIVE BOARD MAKING A DIFFERENCE Developing people: To foster a Mark Walport The Wellcome Trust’s mission is research community and individual Director to foster and promote research with researchers who can contribute to the advancement and use of knowledge Ted Bianco the aim of improving human and Director of Technology Transfer animal health.
    [Show full text]
  • Uman Enome News
    uman enome news ISSN:l050-6101 Vol. 3, No.1, May 1991 DOE Holds Contractor-Grantee Workshop Physical Mapping Efforts Going Well; Gels Increasing Sequencing Efficiency he DOE Human Genome Prograll1 held its second Contractor-Grantee Workshop Charles R. Cantor and HGMIS gratefully Tin Santa Fe, New Mexico, on February l7-W. More than 200 program-sponsored acknowledge contribu­ scientists attended the meeting, in addition to invited guests and industry represen­ tions to this article by tatives. DOE-supported human genome research projects are conducted at 7 DOE Elbert W. Branscomb, national laboratories (including its 3 human genome centers), 37 major universities, Anthony V. Carrano, and 32 companies through collaborations and awards. Projects were represented by Leroy E. Hood, oral presentations or posters. Robert K. Moyzis, and Robert J. Robbins. Six platform sessions focused on the more focus is needed on the immediate following: informatics needs of ongoing biology projects. • physical mapping progress, Many parallel efforts under way in cloning, • large DNA fragment cloning, informatics, mapping, and sequencing will • strategies for preparing samples for further improve the technologies required for efficient DNA sequencing, genomics. Program participants feel that this situation is healthy at present and that a few • new methods for a variety of genome efforts, • DNA sequencing instrumentation, and In This fssue .•. • database and computer algorithm needs for existing or projected genome Page Genome News research. 1 DOE Holds Contractor-Grantee Workshop David Galas, Associate Director, Office of 5 LANL, Life Technologies Approve CRADA Health and Environmental Research (OHER), 6 Conncil on Competitiveness Urges Action spoke about the relationship between the 7 Moore Calls Tech Transfer Critical to Fntnre' Human Genome Program and other OHER 8 NIH Discusses eDNA Role with Invited Group programs.
    [Show full text]
  • A DNA Database in the NHS: Your Freedom up for Sale?
    A DNA database in the NHS: Your freedom up for sale? May 2013 In April 2013, the Caldicott Committee, including Government Chief Scientist Sir Mark Walport, proposed new rules for data-sharing which would allow the Government to build a DNA database of the whole population of England in the NHS by stealth.1 The plan is to make NHS medical records and people’s genetic information available to commercial companies and to use public-private partnerships to build a system where all private information about every citizen is also accessible to the police, social workers, security services and Government. The Wellcome Trust, which was involved in the Human Genome Project and was led by Walport for ten years, has produced a plan which involves including a variant file, containing the whole genome of every person minus the reference genome, as an attachment to every medical record in the NHS in England.2 This data would be made available to ‘researchers’ (including commercial companies) for data-mining in the cloud and personalised risk assessments would be returned to individuals. The aim is to transform the NHS in line with proposals developed more than a decade ago by former GlaxoSmithKline Chairman Sir Richard Sykes. This is expected to massively expand the market for medicines, medical tests and other products, such as supplements and cholesterol-lowering margarines, by allowing products to be marketed to individuals based on personal risk assessments, created using statistical analysis of genetic data, medical records and other health information. The proposal to build a DNA database in the NHS was endorsed by the Human Genomics Strategy Group in 20123,4 and the Government (led by Prime Minister David Cameron) has quietly adopted this recommendation without telling members of the public.
    [Show full text]
  • (Title of the Thesis)*
    THE OPTIMALITY OF DECISION MAKING DURING MOTOR LEARNING by Joshua Brent Moskowitz A thesis submitted to the Department of Psychology in conformity with the requirements for the degree of Master of Science Queen’s University Kingston, Ontario, Canada (June, 2016) Copyright ©Joshua B. Moskowitz, 2016 Abstract In our daily lives, we often must predict how well we are going to perform in the future based on an evaluation of our current performance and an assessment of how much we will improve with practice. Such predictions can be used to decide whether to invest our time and energy in learning and, if we opt to invest, what rewards we may gain. This thesis investigated whether people are capable of tracking their own learning (i.e. current and future motor ability) and exploiting that information to make decisions related to task reward. In experiment one, participants performed a target aiming task under a visuomotor rotation such that they initially missed the target but gradually improved. After briefly practicing the task, they were asked to selected rewards for hits and misses applied to subsequent performance in the task, where selecting a higher reward for hits came at a cost of receiving a lower reward for misses. We found that participants made decisions that were in the direction of optimal and therefore demonstrated knowledge of future task performance. In experiment two, participants learned a novel target aiming task in which they were rewarded for target hits. Every five trials, they could choose a target size which varied inversely with reward value. Although participants’ decisions deviated from optimal, a model suggested that they took into account both past performance, and predicted future performance, when making their decisions.
    [Show full text]
  • Vol 9 No 1 Spring
    A PUBLICATION OF THE AMERICAN SOCIETY FOR MATRIX BIOLOGY SPRING 2010, VOLUME 9, NO. 1 President’s Letter Expanding the Society’s Value to You and Your Role in the Society Since its inception in 2001, the principal function of the ASMB has been to organize the OFFICERS biennial meeting. The value of this meeting to our members cannot be understated. The ASMB meeting has emerged as the matrix-centric President: meeting in North America, and it provides an William Parks (2010) open venue for students, postdocs, fellows, and junior faculty to present their work and to inter- act with established investigators. Speaking for Vice Pres/President Elect myself, I very much look forward to the ASMB Jean Schwarzbauer (2010) meeting, not only because I get to see many Bill Parks friends, but also to hear a lot of incredibly good science. This year’s meeting will be no excep- Past President: tion and promises to be truly outstanding. I applaud Jean Schwarzbauer and the Renato Iozzo (2010) rest of the Program Committee for putting together an exciting meeting loaded with interesting topics and great speakers (please check out the program here). By organizing the meeting, ASMB provides value to you, the membership, but I Secretary/Treasurer think we–the Society–should always be looking to do more; that is, to provide more Joanne Murphy-Ullrich (2011) bang for your dues buck. For this year’s meeting, we have expanded the Travel Awards that will be given to trainees in recognition of outstanding research, and we recently established merit-based Minority Scholarships that will be awarded to eli- Council Members gible students and postdocs.
    [Show full text]
  • Flexible Corticospinal Control of Muscles
    Flexible Corticospinal Control of Muscles Najja J. Marshall Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy under the Executive Committee of the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2021 © 2021 Najja J. Marshall All Rights Reserved Abstract Flexible Corticospinal Control of Muscles Najja J. Marshall The exceptional abilities of top-tier athletes – from Simone Biles’ dizzying gymnastics to LeBron James’ gravity-defying bounds – can easily lead one to forget to marvel at the exceptional breadth of everyday movements. Whether holding a cup of coffee, reaching out to grab a falling object, or cycling at a quick clip, every motor action requires activating multiple muscles with the appropriate intensity and timing to move each limb or counteract the weight of an object. These actions are planned and executed by the motor cortex, which transmits its intentions to motoneurons in the spinal cord, which ultimately drive muscle contractions. A central problem in neuroscience is precisely how neural activity in cortex and the spinal cord gives rise to this diverse range of behaviors. At the level of spinal cord, this problem is considered to be well understood. A foundational tenet in motor control asserts that motoneurons are controlled by a single input to which they respond in a reliable and predictable manner to drive muscle activity, akin to the way that depressing a gas pedal by the same degree accelerates a car to a predictable speed. Theories of how motor cortex flexibly generates different behaviors are less firmly developed, but the available evidence indicates that cortical neurons are coordinated in a similarly simplistic, well-preserved manner.
    [Show full text]
  • Cold Spring Harbor Symposia on Quantitative Biology, Volume LXXIX: Cognition
    This is a free sample of content from Cold Spring Harbor Symposia on Quantitative Biology, Volume LXXIX: Cognition. Click here for more information on how to buy the book. COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY VOLUME LXXIX Cognition symposium.cshlp.org Symposium organizers and Proceedings editors: Cori Bargmann (The Rockefeller University), Daphne Bavelier (University of Geneva, Switzerland, and University of Rochester), Terrence Sejnowski (The Salk Institute for Biological Studies), and David Stewart and Bruce Stillman (Cold Spring Harbor Laboratory) COLD SPRING HARBOR LABORATORY PRESS 2014 © 2014 by Cold Spring Harbor Laboratory Press. All rights reserved. This is a free sample of content from Cold Spring Harbor Symposia on Quantitative Biology, Volume LXXIX: Cognition. Click here for more information on how to buy the book. COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY VOLUME LXXIX # 2014 by Cold Spring Harbor Laboratory Press International Standard Book Number 978-1-621821-26-7 (cloth) International Standard Book Number 978-1-621821-27-4 (paper) International Standard Serial Number 0091-7451 Library of Congress Catalog Card Number 34-8174 Printed in the United States of America All rights reserved COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY Founded in 1933 by REGINALD G. HARRIS Director of the Biological Laboratory 1924 to 1936 Previous Symposia Volumes I (1933) Surface Phenomena XXXIX (1974) Tumor Viruses II (1934) Aspects of Growth XL (1975) The Synapse III (1935) Photochemical Reactions XLI (1976) Origins
    [Show full text]
  • 2019-2020 PO No
    HOLY CROSS COLLEGE (AUTONOMOUS) Affiliated to Bharathidasan University Nationally Accredited (3rd Cycle) with 'A' Grade by NAAC College with Potential for Excellence. Tiruchirappalli - 620002. PG DEPARTMENT OF BIOCHEMISTRY Programme: M.Sc. BIOCHEMISTRY 2019-2020 PO No. Programme Outcomes Upon completion of the B.Sc. Degree Programme, the graduate will be able to PO-1 To enable to get quality education in the areas of Biochemistry PO-2 Acquire practical skills to gather information, assess, create and execute new ideas to develop entrepreneurial skills. PO-3 Gain Proficiency in basic laboratory techniques and able to apply the scientific method on lab to land PO-4 Inculcate a domestic and international perspective and be competent enough in the area of life sciences. PO-5 Learn to recognize potential laboratory safety and conserve nature and the environment. PSO No. Programme Specific Outcomes Upon completion of these courses the student would PSO-1 Will use current biochemical and molecular techniques and carry out experiments PSO-2 Monitoring the changes in modern life styles leads to modern diseases PSO-3 Develop skills in cultivation of plants. PSO-4 Prepare them to do higher studies in other biological fields like Genetic, Entomology, Biological Oceanography etc PSO-5 Developed critical thinking skills/laboratory techniques to be capable of designing, carrying out ,interpreting scientific experiments 1 HOLY CROSS COLLEGE (AUTONOMOUS) PG DEPARTMENT OF BIOCHEMISTRY (Students admitted from the year 2018 onwards) M.Sc. Biochemistry-Course
    [Show full text]
  • Wellcome Investigators March 2011
    Wellcome Trust Investigator Awards Feedback from Expert Review Group members 28 March 2011 1 Roughly 7 months between application and final outcome The Expert Review Groups 1. Cell and Developmental Biology 2. Cellular and Molecular Neuroscience (Zaf Bashir) 3. Cognitive Neuroscience and Mental Health 4. Genetics, Genomics and Population Research (George Davey Smith) 5. Immune Systems in Health and Disease (David Wraith) 6. Molecular Basis of Cell Function 7. Pathogen Biology and Disease Transmission 8. Physiology in Health and Disease (Paul Martin) 9. Population and Public Health (Rona Campbell) 2 Summary Feedback from ERG Panels • The bar is very high across all nine panels • Track record led - CV must demonstrate a substantial impact of your research (e.g. high impact journals, record of ground breaking research, clear upward trajectory etc) To paraphrase Walport ‘to support scientists with the best track records, obviously appropriate to the stage in their career’ • Notable esteem factors (but note ‘several FRSs were not shortlisted’) • Your novelty of your research vision is CRUCIAL. Don’t just carry on doing more of the same • The Trust is not averse to risk (but what about ERG panel members?) • Success rate for short-listing for interview is ~15-25% at Senior Investigator level (3-5 proposals shortlisted from each ERG) • Fewer New Investigator than Senior Investigator applications – an opportunity? • There are fewer applications overall for the second round, but ‘the bar will not be lowered’ The Challenge UoB has roughly 45 existing
    [Show full text]
  • Conference Ontyph Id
    10th INTERNATIONAL CONFERENCE ON TYPH ID & OTHER INVASIVE SALMONELLOSES April 4–6, 2017 | Kampala, Uganda 10th INTERNATIONAL CONFERENCE ON TYPH ID & OTHER INVASIVE SALMONELLOSES WELCOME April 4–6, 2017 | Kampala, Uganda THE WORLD NEEDS ACTION ON TYPHOID — BUILDING EVIDENCE AND REFINING STRATEGIES The Coalition against Typhoid, housed at the Sabin Vaccine Institute, welcomes you to the 10th International Conference on Typhoid and Other Invasive Salmonelloses. We are pleased to provide a forum for more than 300 researchers, policy makers, immunization managers and advocates to come together to share the latest developments and best strategies to reduce the burden of typhoid, paratyphoid and nontyphoidal salmonelloses (NTS) on communities around the world. The conference theme, “From Evidence to Action,” is timely as we prepare for the introduction of new typhoid conjugate vaccines. The research, evidence and ideas shared this week in Kampala will provide the foundation for global action against typhoid, paratyphoid and NTS. Together, we will review crucial developments to reduce the global burden of these diseases, including results from major surveillance projects in Africa and Asia, the potential of human infection models and strategies for countering antibiotic resistance. The program will also highlight outbreak control methods, exciting innovations in diagnostics, water, sanitation and hygiene strategies for prevention, and policy measures aimed at accelerating the implementation of these interventions. The coming availability of a new generation of typhoid conjugate vaccines makes this a pivotal moment for global action on typhoid. These promising new vaccines offer important advantages over prior vaccines, including longer duration of protection, the ability to protect young children, and the potential for administration with other vaccines in routine immunization of infants.
    [Show full text]
  • Adrenaline Stimulates Glucagon Secretion by Tpc2-Dependent
    1128 Diabetes Volume 67, June 2018 Adrenaline Stimulates Glucagon Secretion by Tpc2- Dependent Ca2+ Mobilization From Acidic Stores in Pancreatic a-Cells Alexander Hamilton,1 Quan Zhang,1 Albert Salehi,2 Mara Willems,1 Jakob G. Knudsen,1 Anna K. Ringgaard,3,4 Caroline E. Chapman,1 Alejandro Gonzalez-Alvarez,1 Nicoletta C. Surdo,5 Manuela Zaccolo,5 Davide Basco,6 Paul R.V. Johnson,1,7 Reshma Ramracheya,1 Guy A. Rutter,8 Antony Galione,9 Patrik Rorsman,1,2,7 and Andrei I. Tarasov1,7 Diabetes 2018;67:1128–1139 | https://doi.org/10.2337/db17-1102 Adrenaline is a powerful stimulus of glucagon secretion. It The ability of the “fight-or-flight” hormone adrenaline to acts by activation of b-adrenergic receptors, but the down- increase plasma glucose levels by stimulating liver gluconeo- stream mechanisms have only been partially elucidated. genesis is in part mediated by glucagon, the body’sprincipal Here, we have examined the effects of adrenaline in mouse hyperglycemic hormone (1). Glucagon is secreted by the and human a-cells by a combination of electrophysiology, a-cells of the pancreas (2). Reduced autonomic stimulation 2+ imaging of Ca and PKA activity, and hormone release of glucagon secretion may result in hypoglycemia, a serious measurements. We found that stimulation of glucagon and potentially fatal complication of diabetes (3). It has been secretion correlated with a PKA- and EPAC2-dependent estimated that up to 10% of insulin-treated patients die of (inhibited by PKI and ESI-05, respectively) elevation of hypoglycemia (4). Understanding the mechanism by which [Ca2+] in a-cells, which occurred without stimulation of i adrenaline stimulates glucagon secretion and how it becomes ISLET STUDIES electrical activity and persisted in the absence of extracel- perturbed in patients with diabetes is therefore essential.
    [Show full text]